Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Eur J Clin Pharmacol ; 71(12): 1461-5, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26400679

ABSTRACT

PURPOSE: It is established that omeprazole increases (R)+ warfarin levels with around 10 %. Whether (es)omeprazole also increase the plasma levels of acenocoumarol or phenprocoumon is still uncertain. We analyzed whether addition of (es)omeprazole to acenocoumarol or phenprocoumon increases the international normalized ratio (INR) levels and the risk of overanticoagulation. METHODS: We analyzed all hospital admissions in four teaching hospitals. Patients who used coumarins and pantoprazole or (es)omeprazole simultaneously for at least four consecutive days were included in the study. We analyzed the highest INR level and whether patients had an INR level above six. We compared patients using omeprazole or esomeprazole with patients using pantoprazole, because for pantoprazole, no interaction has been reported. RESULTS: We analyzed 5747 admissions with 4540 patients using one of the drug combinations. For acenocoumarol (4578 admissions), no significant differences were found between users of esomeprazole, omeprazole, and pantoprazole. For phenprocoumon (1169 admissions), the highest INR measured was significantly higher in users of esomeprazole than in users of pantoprazole (4.7 versus 4.3; p = 0.035). No significant difference was found with omeprazole versus pantoprazole (4.3 versus 4.3; p = 0.66). A non-significant association was found between the esomeprazole dose and the highest INR level (p = 0.055). The risk of an INR above six did not differ significantly between esomeprazole and pantoprazole (27.7 % versus 22.9 %; p = 0.34). CONCLUSIONS: The use of esomeprazole simultaneously with phenprocoumon during hospital admissions might increase the anticoagulant effect. The clinical relevance seems to be limited, because no statistically significant increased risk of overanticoagulation was found.


Subject(s)
Acenocoumarol/adverse effects , Anticoagulants/adverse effects , Esomeprazole/adverse effects , Phenprocoumon/adverse effects , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects , Acenocoumarol/administration & dosage , Aged , Aged, 80 and over , Anti-Ulcer Agents/administration & dosage , Anti-Ulcer Agents/adverse effects , Anticoagulants/administration & dosage , Dose-Response Relationship, Drug , Drug Interactions , Esomeprazole/administration & dosage , Female , Hospitalization , Hospitals, Teaching , Humans , International Normalized Ratio , Male , Omeprazole/administration & dosage , Omeprazole/adverse effects , Pantoprazole , Phenprocoumon/administration & dosage
2.
Eur Respir J ; 35(6): 1346-53, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19840963

ABSTRACT

The authors determined the positive predictive value (PPV) for progression to tuberculosis (TB) of two interferon-gamma release assays (IGRAs), QuantiFERON-TB Gold In-tube (QFT-GIT) and T-SPOT.TB, and the tuberculin skin test (TST) in immigrants contacts. Immigrant close contacts of sputum smear-positive TB patients were included when aged > or =16 yrs and their TST result was > or =5 mm 0 or 3 months after diagnosis of the index patient. Contacts were followed for the next 2 yrs for development of TB disease. Of 339 immigrant contacts with TST > or =5 mm, 324 and 299 had valid results of QFT-GIT and T-SPOT.TB, respectively. Nine contacts developed active TB. One patient had not been tested with TST, while another patient had not been tested with QFT-GIT and T-SPOT.TB. The PPV for progression to TB during this period was 9/288 = 3.1% (95% CI 1.3-5.0%) for TST > or =10 mm, 7/184 = 3.8% (95% CI 1.7-5.9%) for TST > or =15 mm, 5/178 = 2.8% (95% CI 1.0-4.6%) for QFT-GIT and 6/181 = 3.3% (95% CI 1.3-5.3%) for T-SPOT.TB. Sensitivity was 100%, 88%, 63% and 75%, respectively. The predictive values of QFT-GIT, T-SPOT.TB and TST for progression to TB disease among immigrant close contacts were comparable.


Subject(s)
Contact Tracing/methods , Contact Tracing/statistics & numerical data , Emigrants and Immigrants/statistics & numerical data , Interferon-gamma/metabolism , Tuberculin Test , Tuberculosis, Pulmonary , Adolescent , Adult , Enzyme-Linked Immunosorbent Assay , Follow-Up Studies , Humans , Incidence , Netherlands/epidemiology , Predictive Value of Tests , Prospective Studies , Reagent Kits, Diagnostic , Risk Factors , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/transmission , Young Adult
3.
Int J Tuberc Lung Dis ; 13(7): 820-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19555530

ABSTRACT

OBJECTIVE: To assess the association between remote exposure to tuberculosis (TB) and results of the tuberculin skin test (TST), and two interferon-gamma release assays (IGRAs)-QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB-in immigrant contacts of sputum smear-positive TB patients. METHODS: Immigrants aged >or=16 years in close contact with smear-positive TB patients were included. QFT-GIT and T-SPOT.TB were performed if the TST induration size was >or=5 mm. Associations between test results and origin from an endemic country were assessed. RESULTS: Of 433 close contacts, 322 (74%) had TST >or=5 mm, of whom, 282 (88%) had valid test results for all assays. Positive QFT-GIT results were obtained for 152/282 (54%) and positive T-SPOT.TB for 168/282 (60%). After adjustment for age, sex and recent contact, positive IGRA results and TST results >/=10 mm were found to be more frequent among immigrants who originated from Africa, in particular sub-Saharan Africa. CONCLUSION: When IGRAs are used to determine latent TB infection in foreign-born individuals, positive findings not only relate to recent TB infection, but also reflect prior TB exposure in the country of origin. This late reactivity will limit their usefulness in contact investigations among immigrants originating from endemic areas.


Subject(s)
Contact Tracing , Interferon-gamma/blood , Mass Screening/methods , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Pulmonary/transmission , Adolescent , Adult , Chi-Square Distribution , Female , Humans , Male , Middle Aged , Sputum/microbiology , Transients and Migrants , Tuberculin Test , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/diagnosis
4.
Int J Tuberc Lung Dis ; 12(11): 1286-94, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18926039

ABSTRACT

SETTING: Following a large-scale contact investigation, individuals with a positive tuberculin skin test (TST) result were offered preventive tuberculosis treatment. OBJECTIVE: To investigate the effect of isoniazid (INH) treatment and the effect of time on interferon gamma release assay (IGRA) results during follow-up. DESIGN: TST-positive subjects (n = 122) detected during the large-scale contact investigation were included in the study. Blood was obtained every 6 months over 2 years to perform both tests. RESULTS: Preventive INH treatment was completed by 36 of the 122 (29.5%) subjects, 71 (58.2%) were followed up with 6-monthly X-ray screening and 15 (12.3%) did not complete INH treatment. The overall percentage of individuals with a positive result remained stable during the 2 years, at approximately 45-50%, but individual responses varied over time. The majority of initially low IGRA results remained below the cut-off value, initially high IGRA results remained positive, while initially intermediate IGRA results were followed by more dynamic patterns. CONCLUSION: This study showed a highly variable pattern of IGRA responses over time and suggests limited value for their use during follow-up of latently infected individuals. However, the significance of different kinetic patterns observed among subjects with intermediate initial IGRA results warrants further study.


Subject(s)
Antitubercular Agents/pharmacology , Drug Monitoring/methods , Interferon-gamma/blood , Isoniazid/pharmacology , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Follow-Up Studies , Humans , Immunoassay/methods , Reagent Kits, Diagnostic , Reproducibility of Results , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...